October 11, 2018
Sonoran Biosciences welcomes three new members to its Board of Directors
Sonoran Biosciences, Inc., a preclinical-stage pharmaceutical company developing a novel antibacterial gel antibacterial gel for the prevention and treatment of surgical site infection, today announced it is welcoming Michael Myers, Gregory Stea, and Joseph Cooper to its Board of Directors. The new Directors have significant experience in senior executive positions in the pharmaceutical industry. They are joined on the Board by CEO Derek Overstreet and Chief Medical Officer Alex McLaren, who are both co-founders of the company.
Dr. Myers is pharmaceutical executive with over 30 years of experience in drug delivery and specialty pharmaceuticals. From 2003 to 2015, he served as CEO of Innocoll, Inc., which developed two locally applied pharmaceutical formulations based on collagen sponge through Phase 3 clinical trials for prevention of surgical site infection and treatment of acute, postoperative pain. Under his leadership, Innocoll went public in 2014. Prior to his time at Innocoll, Dr. Myers was president of the drug delivery division of West Pharmaceutical Services, president of pharmaceutical operations for Fuisz Technologies (Biovail), and held executive positions in Flamel Technologies and Elan Corporation. Dr. Myers earned his Ph.D. in Chemistry from the University College Cork. Dr. Myers also serves on the Board of Directors of Wellesley Pharmaceuticals and Venkor Pharmaceuticals.
Mr. Stea is a pharmaceutical executive with over 30 years of experience in sales and commercial operations. From 2009 to 2015, he served as Senior Vice President of Commercial Operations for Cubist, which was acquired by Merck in 2015 for $9.5 billion. In this role, Mr. Stea was responsible for leading all commercial operations, including the launch and sales of Cubicin, Zerbaxa and Sivextro. During this time he was also a member of the Cubist Operating Committee which was responsible for the company’s overall strategy. Mr. Stea served in other leadership roles at Cubist from 2002 to 2009 and at Amgen, where he was the first employee of its sales organization in 1988. Mr. Stea earned his Bachelor’s Degree in Business Administration from Temple University and completed the University of Michigan’s Executive Education program as well as Harvard Business School’s program in leadership and strategy in pharmaceuticals and biotechnology. He most recently served as an advisor to La Jolla Pharmaceutical Company in preparing for commercialization of their first drug, Angiotensin II (Giapreza), and he currently serves on the Board of Directors of Achaogen.
Mr. Cooper is a pharmaceutical executive with over 25 years of experience in business development and operational roles. He is currently the Chief Business Officer for NuvOx Pharma and previously served as interim CEO and an advisor to Sonoran Biosciences. From 1996 to 2010, Mr. Cooper served as Executive Vice President of Corporate and Product Development at Medicis Pharmaceutical Corporation, where he was responsible for corporate development, clinical and technical operations, business unit management, as well as frequent representation for the company with investors and equity analysts. During his tenure at Medicis, the company’s revenues grew to over $600 million annually. Mr. Cooper is earned his bachelor’s degree in Business Administration, Management and Operations from Northeastern Illinois University and holds an MBA from the Executive Program at Arizona State University.
About Sonoran Biosciences, Inc.
Sonoran Biosciences is a preclinical-stage pharmaceutical company developing a novel antibacterial gel for the prevention and treatment of surgical site infection (SSI). The company’s lead product SBG002 is an injectable sustained-release gel containing tobramycin and vancomycin designed for direct application in surgical sites. SBG002 has the potential to become a first-in-class product for prevention of SSI, including after orthopaedic, cardiac, and colorectal surgery.